Vesta Therapeutics is a privately held company developing cell therapeutics for liver repair and regeneration. The Company's technology is centered on the isolation, expansion, and cryopreservation of liver cells (human hepatocytes) obtained from organ donor livers that are not suitable for whole organ transplantation. Clinicians in academic settings have found that, following administration, human hepatocytes engraft and create new functioning liver tissue, which may provide a bridge to transplant or in some cases, eliminate the need for a liver transplant. The Food and Drug Administration has allowed the Company's Investigational New Drug (IND) application for a Phase I clinical trial of cryopreserved, allogeneic human liver cells for the treatment of patients with cirrhosis and end-stage liver disease.
Vesta is an equal opportunity employer. Vesta is committed to equal employment opportunities in all employment practices and decisions including recruitment, hiring, promotion, training, compensation, and disciplinary action. Vesta does not discriminate on the basis of race, religion, national origin, color, age, sex, disability, veteran status, sexual orientation, genetic information, or any other legally protected characteristic. Employees are our most valuable resource. We are committed to fostering an environment where recognition, innovation, communication, and an entrepreneurial spirit are encouraged and rewarded. We attract and retain qualified candidates by providing competitive cash compensation and benefits packages. It is the Company's policy to provide employees with opportunities to develop professionally by providing them with tuition reimbursement and the opportunity to attend professional conferences.
